title: Changes in the proportions of CD4(+)T cell subsets defined by CD127 and CD25 expression during HBV infection.
abstract: CD4(+)T cell counts are closely related to the progression of HBV infection. Here, we investigated how the proportions of three CD4(+)T cell subsets - CD127(-)CD25(-), CD127(+)CD25(low/-) and CD127(low)CD25(high) - changed during HBV infection, as is little known. Compared with healthy controls, the proportions of CD127(-)CD25(-) in chronic hepatitis B (CHB) patients and HBV carriers significantly increased, while that of CD127(+)CD25(low/-) significantly decreased. The proportion of CD127(low)CD25(high) in CHB patients was significantly higher than those in HBV carriers or healthy controls. Compared with HBV-DNA negative group, the proportion of CD127(-)CD25(-) in positive group significantly decreased and that of CD127(+)CD25(low/-) significantly increased. In the follow-up study for CHB patients treated with interferon-α2b for 12 weeks or 24 weeks, the proportions of CD127(-)CD25(-) significantly decreased, while that of CD127(low/-)CD25(high) significantly increased. The results suggested that specific changes in the fraction of CD4(+)T cell subsets expressing CD127 and/or CD25 were associated with hepatitis B progression.
authors: Department of Laboratory Medicine, The Taizhou People's Hospital, Taizhou City, Jiangsu Province 225300, China.
authors: Hong-Tao
authors: HT
authors: Xu
authors: Jun
authors: J
authors: Ye
authors: Ya-Bao
authors: YB
authors: Chen
authors: Li-Xing
authors: LX
authors: Zhang
authors: Jun-Xing
authors: JX
authors: Huang
authors: Jian-Chun
authors: JC
authors: Xian
authors: Ling
authors: L
authors: Liu
authors: Hai-Lin
authors: HL
authors: Peng
authors: Lin
authors: L
authors: Li
authors: Mei
authors: M
authors: Lin
authors: Jing-Hua
authors: JH
authors: Huang
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002681:China; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006515:Hepatitis B virus / Q000276:immunology* / Q000472:pathogenicity; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D053699:Interleukin-7 Receptor alpha Subunit / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D053645:Interleukin-2 Receptor alpha Subunit; D053699:Interleukin-7 Receptor alpha Subunit; C076799:interferon-alpha 8